Table 3 Distribution of the study parameters in PET/CT examinations of prior BAT negative patients (n = 214) depending on the BAT activity.

Parameter (patient n)^a	New onset of BAT activity (n or mean ± SD )			Regression (p-value)
Parameter (patient n)^a	None	Low	High	Univariate	Multivariate^b
Total	193	13	8	N/A
Active BAT depots (range)	0	3–6	4–6	N/A
SUVmean of the active BAT depots	N/A	1.9 ± 0.2	2.5 ± 0.4	N/A
Age (years)	54 ± 18	40 ± 15	25 ± 10	< 0.001*	< 0.001*
BMI (kg/m², n = 209)	25.9 ± 5.5	25.5 ± 6.6	22.5 ± 3.6	0.22
Sex (females)	84	7	7	0.06
Lymphoma group
Mature B-cell lymphoma	101	5	0	0.06
Hodgkin lymphoma	76	8	6
Mature T-cell lymphoma	6	0	1
Other lymphoma	10	0	1
Season of PET
Spring	55	4	2	0.48
Summer	47	3	2
Autumn	49	2	0
Winter	42	4	4
Disease activity (n = 189)	63	3	2	0.73
No preceding therapy	24	6	0	0.002*	0.03*
Radiotherapy	27	2	1	0.98
ABVD regimen	21	2	2	0.43
CHOP/CHLIP regimen	64	1	1	0.08
BEACOPP regimen	29	1	4	0.02*	0.86
Rituximab	77	2	0	0.02*	0.42
Cytarabine	18	1	1	0.93
Steroids	116	5	6	0.20
Beta-receptor therapy (n = 209)
Inhibition	32	0	0	0.30
No therapy	152	13	8
Beta-receptor agonist	4	0	0
Thyroid dysfunction (n = 208)
Hypothyroidism	34	0	2	0.47
Euthyroidism	142	12	6
Hyperthyrodisim	11	1	0
Hyperlipidemia (n = 207)	22	0	0	0.25
Diabetes mellitus (n = 211)	31	0	0	0.13
Hypertension (n = 211)	53	1	0	0.07
Prior Cancer (n = 211)	19	0	0	0.32
Weight change (kg, n = 213)	0.3 ± 7.3	2.5 ± 9.8	− 0.9 ± 13.9	0.65

*Significant, p value of < 0.05, ^apatient number for evaluation of this parameter if divergent from the total patient number, ^bonly significant parameters of the univariate analyses were included.
BAT brown adipose tissue, SUVmean mean standardized uptake value, ABVD regimen doxorubicin, bleomycin, vinblastine, dacarbazine, CHOP/CHLIP regimen cyclophosphamide, doxorubicin, conventional/liposomal vincristine, steroids, BEACOPP regimen bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and steroids, N/A not applicable.

Search